FindTrial
Sign In

intravenous, continuous

2 trials

Sponsors

IHARA MASAFUMI, Ihara Masafumi

Conditions

Acute non-embolic ischemic stroke Lacunar stroke, Non-embolic, Acute, Ischemic strokeCerebral Autosomal Dominant Arteriopathy with Subcortical Infarct and Leukoencephalopathy (CADASIL) adrenomedullin, CADASIL, NOTCH3 gene

Phase 2

Adrenomedullin for ischemic stroke study
Active, not recruitingJPRN-jRCT2051190092
IHARA MASAFUMIAcute non-embolic ischemic stroke Lacunar stroke, Non-embolic, Acute, Ischemic stroke
Start: 2020-01-16Target: 60Updated: 2025-07-18
Adrenomedullin for CADASIL
Active, not recruitingJPRN-jRCT2051210117
Ihara MasafumiCerebral Autosomal Dominant Arteriopathy with Subcortical Infarct and Leukoencephalopathy (CADASIL) adrenomedullin, CADASIL, NOTCH3 gene
Start: 2022-01-06Target: 60Updated: 2025-07-18

Related Papers

Efficacy and safety of adrenomedullin for acute ischemic stroke (AMFIS): a phase 2, randomized, double-blinded, placebo-controlled, clinical trial.
2024-11-133 citations
A multicenter, single-arm, phase II clinical trial of adrenomedullin in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
Cerebral Circulation - Cognition and Behavior2024-01-014 citations